Agilent Plans Expansion of Oligo Manufacturing Capacity
PTSM: Pharmaceutical Technology Sourcing and Management
Agilent Technologies announces plans to build a new oligo manufacturing facility in Colorado that will double current capacity.
Agilent Technologies announced on Aug. 9, 2106 that the company has acquired 20 acres in Weld County, CO, on which it plans to build a pharmaceutical manufacturing facility that will more than double its commercial manufacturing capacity for nucleic acid APIs. The expansion will add 150–200 jobs, the company reports.
"The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases," said Skip Thune, general manager of the company's Nucleic Acids Solutions Division in a press statement. "At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides."
Agilent's 65,000-sq.-ft. facility in Boulder, CO, manufactures oligo APIs for clinical trials. Capabilities include four synthesis/purification trains and two lyophilization units. A commercial GMP plant expansion was completed in 2010 and can produce multi-kilo lots of late-stage clinical materials, as reported on the company website.
Source: Agilent Technologies
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
